Welcome to our dedicated page for Cogent Biosciences news (Ticker: COGT), a resource for investors and traders seeking the latest updates and insights on Cogent Biosciences stock.
Cogent Biosciences, Inc. (Nasdaq: COGT) generates frequent news flow as a biotechnology company developing precision therapies for genetically defined diseases. Its updates often center on the clinical and regulatory progress of bezuclastinib, a selective tyrosine kinase inhibitor designed to inhibit KIT D816V and other KIT exon 17 mutations associated with systemic mastocytosis and advanced gastrointestinal stromal tumors (GIST).
News for COGT commonly includes clinical trial milestones from the pivotal SUMMIT, APEX and PEAK studies. SUMMIT evaluates bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM), APEX in Advanced Systemic Mastocytosis (AdvSM), and PEAK in imatinib-resistant or intolerant GIST in combination with sunitinib. Press releases have highlighted positive top-line results, detailed efficacy and safety data, and plans for New Drug Application (NDA) submissions to the U.S. Food and Drug Administration.
Investors and followers of COGT can also expect regulatory and designation announcements, such as Breakthrough Therapy Designation for bezuclastinib in specific NonAdvSM populations, as well as updates on Expanded Access Programs for eligible GIST and SM patients. Financial and corporate news appears regularly, including equity and convertible note offerings, cash runway commentary, and participation in major healthcare investor conferences like the J.P. Morgan Healthcare Conference and the Jefferies Global Healthcare Conference.
In addition, Cogent issues news on its early-stage pipeline, including a selective and potent FGFR2/3 inhibitor in Phase 1/2 and discovery programs targeting ErbB2, PI3Kα, KRAS and JAK2. For readers tracking COGT, this news page provides an organized view of trial readouts, regulatory plans, financing events and scientific presentations that shape the company’s development trajectory. Bookmark this feed to monitor Cogent’s ongoing disclosures about its precision oncology and hematology programs.
Cogent Biosciences (Nasdaq: COGT) presented preclinical data from four pipeline programs at the AACR 2025 Annual Meeting in Chicago. The presentations included: a pan KRAS(ON) inhibitor showing 90% tumor growth inhibition; CGT6297, a PI3Kα inhibitor targeting H1047R and helical mutations; CGT4859, a selective FGFR2/3 inhibitor currently in Phase 1 trials; and CGT4255, a brain-penetrant ErbB2 inhibitor.
The company also announced two key leadership appointments: Ray Frost as SVP of Market Access and Dr. Adam Boyd as SVP of Corporate Strategy. Additionally, Cogent granted inducement equity awards to five new employees, including nonqualified options to purchase 446,000 shares with a 4-year vesting schedule.
Cogent Biosciences (NASDAQ: COGT) announced four preclinical poster presentations at the upcoming 2025 AACR Annual Meeting in Chicago, scheduled for April 25-30, 2025. The presentations showcase the company's advancement in precision therapies:
- A potent KRAS (ON) inhibitor with selective mutation targeting
- CGT6297: A novel PI3Kα H1047R mutant-selective inhibitor
- CGT4859: A reversible and selective FGFR2/3 inhibitor addressing resistance mutations
- CGT4255: An EGFR sparing, pan-mutant HER2 candidate with potential brain penetration capabilities
Additionally, the company granted an inducement equity award to a new employee, consisting of options to purchase 9,700 shares with a 4-year vesting schedule, approved under Nasdaq Listing Rule 5635(c)(4).
Cogent Biosciences (Nasdaq: COGT) has announced its upcoming participation in a fireside chat at the Leerink Healthcare Conference scheduled for March 12, 2025, at 10:00 a.m. ET. The event will be accessible via webcast on the company's Investors & Media webpage, with replay available for 30 days.
Additionally, the company disclosed an inducement equity grant approved by its Compensation Committee on March 4, 2025. Under Nasdaq Listing Rule 5635(c)(4), a new employee received options to purchase 90,000 shares of Cogent common stock. The option features a 10-year term, with a 4-year vesting schedule: 25% vesting after one year and the remainder vesting monthly over 36 months, contingent on continued employment.
Cogent Biosciences (NASDAQ: COGT) has reported expanded clinical results from the Open Label Extension (OLE) portion of SUMMIT trial, evaluating bezuclastinib in nonadvanced systemic mastocytosis patients. The data, presented at AAAAI/WAO 2025, showed remarkable improvements after 48 weeks of treatment:
Key findings include:
- 65% mean improvement in Total Symptom Score (TSS)
- 88% of patients achieved >50% TSS reduction
- 94% of patients exceeded 30% TSS reduction
- 63% reduction in most severe symptoms
The trial involved patients with median age 52 years (range 36-76). Safety data from August 2024 showed mostly low-grade, reversible adverse events, primarily hair discoloration and transaminase elevations. The median treatment duration was 56 weeks for the active arm and 40 weeks for placebo crossover patients. Top-line results from SUMMIT Part 2 registration-directed trial are expected in July 2025.
Cogent Biosciences (NASDAQ: COGT) has reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical trials for bezuclastinib. The company expects top-line results from three pivotal trials in 2025: SUMMIT trial (NonAdvSM) in July, APEX trial (AdvSM) in 2H, and PEAK trial (GIST) by year-end.
Clinical highlights include impressive data from the SUMMIT trial showing 56% mean improvement in Total Symptom Score and 89% of patients with >50% decrease in serum tryptase levels. The APEX trial demonstrated 52% overall response rate per mIWG criteria, rising to 83% for patients receiving 100mg BID.
Cogent's pipeline expansion includes a selective KRAS inhibitor (CGT6737) and PI3Kα inhibitor (CGT6297). The company plans to submit IND applications in 2025 for CGT4255 (ErbB2 inhibitor) and CGT6297.
Financially, Cogent reported $287.1 million in cash and equivalents as of December 31, 2024, plus $25 million from an ATM offering in February 2025. This funding is expected to sustain operations into late 2026, well past planned clinical readouts. R&D expenses increased to $232.7 million for 2024, up from $173.8 million in 2023, while net loss widened to $255.9 million from $192.4 million.
Cogent Biosciences (Nasdaq: COGT) has announced an upcoming poster presentation featuring bezuclastinib at the 2025 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) in San Diego. The presentation will focus on a subgroup of patients who received 100mg bezuclastinib for at least 48 weeks in the ongoing Summit Trial, highlighting long-term symptomatic benefits.
The poster, titled 'Efficacy and Safety Results of Adult Patients with NonAdvanced Systemic Mastocytosis Receiving Bezuclastinib 100 mg in the Ongoing Summit Trial: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib,' will be presented on March 1, 2025, from 9:45-10:45am PT at the San Diego Convention Center.
Cogent Biosciences (Nasdaq: COGT), a biotechnology company specializing in precision therapies for genetically defined diseases, has announced its upcoming participation in the Guggenheim SMID Cap Biotech Conference. The company will engage in a fireside chat scheduled for Wednesday, February 5, 2025 at 9:30 a.m. ET in New York.
Interested parties can access a live webcast of the presentation through the Investors & Media section of Cogent's website. The presentation recording will be made available approximately two hours after the event and will remain accessible for 30 days on the company's investor relations platform.
Cogent Biosciences (NASDAQ: COGT) has announced key milestones for 2025, focusing on their lead drug bezuclastinib and other pipeline developments. The company plans to report top-line results from three major clinical trials: the SUMMIT trial for Non-Advanced Systemic Mastocytosis in July, the APEX trial for Advanced Systemic Mastocytosis in H2, and the Phase 3 PEAK trial for second-line GIST by year-end.
The company aims to submit its first New Drug Application (NDA) by the end of 2025. Additionally, Cogent will initiate Expanded Access Programs for SM and GIST patients in Q1 2025. The company is also advancing other pipeline products, including the ongoing Phase 1 trial of CGT4859 (FGFR2 inhibitor) and plans to submit IND applications for their ErbB2 inhibitor (CGT4255) and PI3Kα inhibitor (CGT6737).
Cogent Biosciences (Nasdaq: COGT), a biotechnology company specializing in precision therapies for genetically defined diseases, announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Andrew Robbins, President and CEO, will deliver a presentation on Tuesday, January 14, 2025, at 7:30 a.m. PT/10:30 a.m. ET. The presentation will be accessible via live webcast on the company's Investors & Media webpage, with a replay available for 30 days following the event.
Cogent Biosciences (NASDAQ: COGT) announced updated clinical results from the SUMMIT trial's Open Label Extension (OLE) evaluating bezuclastinib in nonadvanced systemic mastocytosis patients. The data showed significant improvements with 56% mean improvement in Total Symptom Score at 24 weeks, and 76% of patients achieving at least 50% reduction in symptoms.
The study demonstrated rapid pharmacodynamic response with 89% of patients showing >50% decrease in serum tryptase by week 4, and 95% achieving tryptase levels below 20 ng/ml by week 24. The safety profile was favorable with mostly low-grade, reversible adverse events.
SUMMIT Part 2 enrollment completed ahead of schedule with 179 patients enrolled, with top-line results expected in July 2025.